Ibraheem J J, Paalzow L, Tfelt-Hansen P
Eur J Clin Pharmacol. 1985;29(1):61-6. doi: 10.1007/BF00547370.
Ergotamine tartrate 0.5, 0.25 and 0.125 mg was administered i.v. to 6 volunteers in a cross-over study. Its pharmacokinetic characteristics were evaluated from plasma concentration-time data determined by HPLC. The clearance and volume of distribution were independent of the dose. The ratio between blood and plasma ergotamine concentrations in 4 subjects ranged from 0.41-0.67, indicating the lack of binding to blood cells. Ergotamine was found to be a high clearance drug, average 2.21/min/70 kg body wt. suggesting extrahepatic clearance. A possible transient decrease in liver blood flow caused by ergotamine did not seem to affect the linearity of its kinetics.
在一项交叉研究中,对6名志愿者静脉注射了0.5毫克、0.25毫克和0.125毫克的酒石酸麦角胺。通过高效液相色谱法测定血浆浓度-时间数据来评估其药代动力学特征。清除率和分布容积与剂量无关。4名受试者血液和血浆中麦角胺浓度的比值在0.41至0.67之间,表明其与血细胞无结合。发现麦角胺是一种高清除率药物,平均为2.21/分钟/70千克体重,提示存在肝外清除。麦角胺引起的肝血流量可能的短暂减少似乎并未影响其动力学的线性。